You'll note the 34 pulls thru, the pricing data runs back to 500 Double Hull and that's the shove off for most direction changes as shown in this graph of IMGN... Expecting significant upside based on my daily momentum model.
brschultz
When i discovered the DoubleHull MA, it then occured to me why & how the 34 Week SMA bounced upwards when under the 340 week SMA as shown in weekly graph of IMGN.
My personal theory & momentum models suggest major upside is coming for IMGN - i bought calls.
brschultz aka markettimer777
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
IMGN
